journal
MENU ▼
Read by QxMD icon Read
search

Circulation

journal
https://www.readbyqxmd.com/read/28533303/cardiopulmonary-resuscitation-in-adults-and-children-with-mechanical-circulatory-support-a-scientific-statement-from-the-american-heart-association
#1
REVIEW
Mary Ann Peberdy, Jason A Gluck, Joseph P Ornato, Christian A Bermudez, Russell E Griffin, Vigneshwar Kasirajan, Richard E Kerber, Eldrin F Lewis, Mark S Link, Corinne Miller, Jeffrey J Teuteberg, Ravi Thiagarajan, Robert M Weiss, Brian O'Neil
Cardiac arrest in patients on mechanical support is a new phenomenon brought about by the increased use of this therapy in patients with end-stage heart failure. This American Heart Association scientific statement highlights the recognition and treatment of cardiovascular collapse or cardiopulmonary arrest in an adult or pediatric patient who has a ventricular assist device or total artificial heart. Specific, expert consensus recommendations are provided for the role of external chest compressions in such patients...
May 22, 2017: Circulation
https://www.readbyqxmd.com/read/28522450/lower-risk-of-heart-failure-and-death-in-patients-initiated-on-sglt-2-inhibitors-versus-other-glucose-lowering-drugs-the-cvd-real-study
#2
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Jørgensen, Marcus Thuresson, Niki Arya, Johan Bodegård, Niklas Hammar, Peter Fenici
Background -Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose co-transporter-2 inhibitor (SGLT-2i) empagliflozin in type 2 diabetes patients with atherosclerotic cardiovascular disease. We compared HHF and death in patients newly initiated on any SGLT-2i versus other glucose lowering drugs (oGLDs) in six countries to determine if these benefits are seen in real-world practice, and across SGLT-2i class. Methods -Data were collected via medical claims, primary care/hospital records and national registries from the US, Norway, Denmark, Sweden, Germany and the UK...
May 18, 2017: Circulation
https://www.readbyqxmd.com/read/28512184/effect-of-intensive-blood-pressure-lowering-on-left-ventricular-hypertrophy-in-patients-with-hypertension-the-systolic-blood-pressure-intervention-sprint-trial
#3
Elsayed Z Soliman, Walter T Ambrosius, William C Cushman, Zhu-Ming Zhang, Jeffrey T Bates, Javier A Neyra, Thaddeus Y Carson, Leonardo Tamariz, Lama Ghazi, Monique E Cho, Brian P Shapiro, Jiang He, Lawrence J Fine, Cora E Lewis
Background -It is currently unknown whether intensive blood pressure (BP) lowering beyond that recommended would lead to more lowering of the risk of Left ventricular hypertrophy (LVH) in patients with hypertension, and whether reducing the risk of LVH explains the reported cardiovascular disease (CVD) benefits of intensive BP lowering in this population. Methods -This analysis included 8,164 participants (mean age 67.9 years, 35.3% women, 31.2% blacks) with hypertension but no diabetes from the Systolic Blood Pressure Intervention (SPRINT) Trial; 4,086 randomly assigned to intensive BP lowering (target systolic BP<120mmHg) and 4,078 assigned to standard BP lowering (target systolic BP <140mmHg)...
May 16, 2017: Circulation
https://www.readbyqxmd.com/read/28500271/causal-associations-of-adiposity-and-body-fat-distribution-with-coronary-heart-disease-stroke-subtypes-and-type-2-diabetes-a-mendelian-randomization-analysis
#4
Caroline Dale, Ghazaleh Fatemifar, Tom Palmer, Jonathan White, David Prieto-Merino, Delilah Zabaneh, Jorgen E L Engmann, Tina Shah, Andrew Wong, Helen R Warren, Stela McLachlan, Stella Trompet, Max Moldovan, Richard W Morris, Reecha Sofat, Meena Kumari, Elina Hyppönen, Barbara J Jefferis, Tom R Gaunt, Yoav Ben-Shlomo, Ang Zhou, Aleksandra Gentry-Maharaj, Andy Ryan, Renée de Mutsert, Raymond Noordam, Mark J Caulfield, J Wouter Jukema, Bradford B Worrall, Patricia B Munroe, Usha Menon, Chris Power, Diana Kuh, Debbie A Lawlor, Steve E Humphries, Dennis O Mook-Kanamori, George Davey Smith, Naveed Sattar, Mika Kivimaki, Jacqueline F Price, Frank Dudbridge, Aroon D Hingorani, Michael V Holmes, Juan-Pablo Casas
Background -Implications of different adiposity measures on cardiovascular disease aetiology remain unclear. In this paper we quantify and contrast causal associations of central adiposity (waist:hip ratio adjusted for BMI (WHRadjBMI)) and general adiposity (body mass index (BMI)) with cardiometabolic disease. Methods -97 independent single nucleotide polymorphisms (SNPs) for BMI and 49 SNPs for WHRadjBMI were used to conduct Mendelian randomization analyses in 14 prospective studies supplemented with CHD data from CARDIoGRAMplusC4D (combined total 66,842 cases), stroke from METASTROKE (12,389 ischaemic stroke cases), type 2 diabetes (T2D) from DIAGRAM (34,840 cases), and lipids from GLGC (213,500 participants) consortia...
May 12, 2017: Circulation
https://www.readbyqxmd.com/read/28487393/potent-thrombolytic-effect-of-n-acetylcysteine-on-arterial-thrombi
#5
Sara Martinez de Lizarrondo, Clément Gakuba, Bradley A Herbig, Yohann Repessé, Carine Ali, Cécile V Denis, Peter Lenting, Emmanuel Touzé, Scott L Diamond, Denis Vivien, Maxime Gauberti
Background -Platelet crosslinking during arterial thrombosis involves von Willebrand Factor (VWF) multimers. Therefore, proteolysis of VWF appears promising to disaggregate platelet-rich thrombi and restore vessel patency in acute thrombotic disorders such as ischemic stroke, acute coronary syndrome or acute limb ischemia. N-Acetylcysteine (NAC, a clinically approved mucolytic drug) can reduce intrachain disulfide bonds in large polymeric proteins. In the present study, we postulated that NAC might cleave the VWF multimers inside occlusive thrombi, thereby leading to their dissolution and arterial recanalization...
May 9, 2017: Circulation
https://www.readbyqxmd.com/read/28487392/epha2-expression-regulates-inflammation-and-fibroproliferative-remodeling-in-atherosclerosis
#6
Alexandra C Finney, Steven D Funk, Jonette Green, Arif Yurdagul, Mohammad A Rana, Rebecca Pistorius, Miriam Henry, Andrew D Yurochko, Christopher B Pattillo, James G Traylor, Jin Chen, Matthew D Woolard, Christopher G Kevil, A Wayne Orr
Background -Atherosclerotic plaque formation results from chronic inflammation and fibroproliferative remodeling in the vascular wall. We previously demonstrated that both human and mouse atherosclerotic plaques show elevated expression of EphA2, a guidance molecule involved in cell-cell interactions and tumorigenesis. Methods -Here, we assessed EphA2's role in atherosclerosis by deleting EphA2 in a mouse model of atherosclerosis (Apoe(-/-)) and by assessing EphA2 function in multiple vascular cell culture models...
May 9, 2017: Circulation
https://www.readbyqxmd.com/read/28487391/functional-characterization-of-the-gucy1a3-coronary-artery-disease-risk-locus
#7
Thorsten Kessler, Jana Wobst, Bernhard Wolf, Juliane Eckhold, Baiba Vilne, Ronja Hollstein, Simon von Ameln, Tan An Dang, Hendrik B Sager, Philipp Moritz Rumpf, Redouane Aherrahrou, Adnan Kastrati, Johan L M Bjoerkegren, Jeanette Erdmann, Aldons J Lusis, Mete Civelek, Frank J Kaiser, Heribert Schunkert
Background -A chromosomal locus at 4q32.1 has been genome-wide significantly associated with coronary artery disease risk. The locus encompasses GUCY1A3, which encodes the α1-subunit of the soluble guanylyl cyclase (sGC), a key enzyme in the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway. The mechanism linking common variants in this region with coronary risk is not known. Methods -Gene and protein expression were analyzed using quantitative polymerase chain reaction (qPCR) and immunoblotting, respectively...
May 9, 2017: Circulation
https://www.readbyqxmd.com/read/28483812/coronary-plaque-characterization-in-psoriasis-reveals-high-risk-features-which-improve-following-treatment-in-a-prospective-observational-study
#8
Joseph B Lerman, Aditya A Joshi, Abhishek Chaturvedi, Tsion M Aberra, Amit K Dey, Justin A Rodante, Taufiq Salahuddin, Jonathan H Chung, Anshuma Rana, Heather L Teague, Jashin J Wu, Martin P Playford, Benjamin N Lockshin, Marcus Y Chen, Veit Sandfort, David A Bluemke, Nehal N Mehta
Background -Psoriasis, a chronic inflammatory disease associated with an accelerated risk of MI, provides an ideal human model to study inflammatory atherogenesis in vivo We hypothesized that the increased cardiovascular risk observed in psoriasis would be partially attributable to an elevated subclinical coronary artery disease (CAD) burden composed of non-calcified plaques with high-risk features. However, inadequate efforts have been made to directly measure CAD in this vulnerable population. As such, we sought to compare total (TB) and non-calcified (NCB) coronary plaque burden, and high-risk plaque (HRP) prevalence, between psoriasis patients (n=105), hyperlipidemic patients eligible for statin therapy under NCEP-ATP III guidelines (n=100) who were ~10 years older, and non-psoriasis healthy volunteers (HV) (n=25)...
May 8, 2017: Circulation
https://www.readbyqxmd.com/read/28476766/effect-of-long-term-metformin-and-lifestyle-in-the-diabetes-prevention-program-and-its-outcome-study-on-coronary-artery-calcium
#9
Ronald B Goldberg, Vanita R Aroda, David A Bluemke, Elizabeth Barrett-Connor, Matthew J Budoff, Jill P Crandall, Dana Dabelea, Edward S Horton, Kieren J Mather, Trevor J Orchard, David Schade, Karol Watson, Marinella Temprosa
Background -Despite the reduced incidence of coronary heart disease (CHD) with intensive risk factor management, people with diabetes and prediabetes remain at increased CHD risk. Diabetes prevention interventions may be needed to reduce CHD risk. This approach was examined in the Diabetes Prevention Program (DPP) and its Outcome Study (DPPOS), a long-term intervention study in 3234 subjects with prediabetes (mean [±SD] age 64±10 yrs) which showed reduced diabetes risk with lifestyle and metformin compared to placebo over 3...
May 5, 2017: Circulation
https://www.readbyqxmd.com/read/28473448/india-and-the-coronary-stent-market-getting-the-price-right
#10
Priya Wadhera, Thomas Alexander, Brahmajee K Nallamothu
On February 13, 2017, India's National Pharmaceutical and Pricing Authority (NPPA) made a landmark decision to fix price ceilings for coronary stents at 7260 rupees for bare metal stents and 29 600 rupees for drug-eluting stents (US equivalents of $108 and $444, respectively).(1,2) Stents had been placed on the National List of Essential Medications (NLEM) in July 2016 by the health ministry.(1) In India, stents turned out to be subject to substantial price markups on their journey from manufacturer to patient, at times exceeding 4 times their original imported value...
May 4, 2017: Circulation
https://www.readbyqxmd.com/read/28473447/insurance-and-cardiovascular-health-time-for-evidence-to-trump-politics
#11
Rishi K Wadhera, Karen E Joynt
The United States is entrenched in a fierce debate over health care reform. The Affordable Care Act (ACA) strove to reduce the number of uninsured, and following its implementation, twenty million Americans gained insurance coverage. Ongoing shifts in health policy imperil these gains. As options for repealing, replacing, or revising the ACA are debated, we aim to outline what is known about the relationship between insurance coverage and cardiovascular (CV) care, the impact of the ACA on CV care, and areas where gaps in our knowledge remain...
May 4, 2017: Circulation
https://www.readbyqxmd.com/read/28473446/human-plasma-thioredoxin-80-increases-with-age-and-in-apoe-mice-induces-inflammation-angiogenesis-and-atherosclerosis
#12
Dominique Couchie, Boris Vaisman, Amna Abderrazak, Dler Faieeq Darweesh Mahmood, Magda M Hamza, Fanny Canesi, Vimala Diderot, Khadija El Hadri, Anne E Nègre-Salvayre, Aurélie Le Page, Tamas Fulop, Alan T Remaley, Mustapha Rouis
Background -Thioredoxin-1 (TRX1), a ubiquitous 12 kDa protein, exerts anti-oxidant and anti-inflammatory effects. In contrast, the truncated form, called TRX80, produced by macrophages induces up-regulation of pro-inflammatory cytokines. TRX80 also promotes the differentiation of mouse peritoneal and human macrophages toward a pro-inflammatory M1 phenotype. Methods -TRX1 and TRX80 plasma levels were determined using specific ELISA. ADAM-17 and ADAM-10 activities were measured using respectively SensoLyte® 520 ADAM10 Activity Assay Kit *Fluorimetric* and InnoZyme™ TACE Activity Kit...
May 4, 2017: Circulation
https://www.readbyqxmd.com/read/28468975/physiology-of-angina-and-its-alleviation-with-nitroglycerine-insights-from-invasive-catheter-laboratory-measurements-during-exercise
#13
Kaleab N Asrress, Rupert Williams, Timothy P Lockie, Muhammed Z Khawaja, Kalpa De Silva, Matthew Lumley, Tiffany Patterson, Satpal S Arri, Sana Ihsan, Howard Ellis, Antoine Guilcher, Brian R Clapp, Philip J Chowienczyk, Sven Plein, Divaka Perera, Michael Marber, Simon R Redwood
Background -The mechanisms governing exercise-induced angina and its alleviation by the most commonly used anti-anginal drug, nitroglycerine (GTN), are incompletely understood. The purpose of this study was to develop a method with which the effects of anti-anginal drugs could be evaluated invasively during physiological exercise to gain further understanding as to the clinical impact of angina and GTN. Methods -40 Patients (mean 65.2±7.6 years) with exertional angina and coronary artery disease underwent cardiac catheterisation via radial access and performed incremental exercise using a supine cycle ergometer...
May 3, 2017: Circulation
https://www.readbyqxmd.com/read/28465288/thirty-day-readmissions-after-endovascular-or-surgical-therapy-for-critical-limb-ischemia-analysis-of-the-2013-2014-nationwide-readmissions-databases
#14
Dhaval Kolte, Kevin F Kennedy, Mehdi H Shishehbor, J Dawn Abbott, Sahil Khera, Peter A Soukas, Shafiq T Mamdani, Omar N Hyder, Douglas E Drachman, Herbert D Aronow
Background -Thirty-day readmission rates have gained increasing importance as a key quality metric. A significant number of patients are hospitalized for the management of critical limb ischemia (CLI), but limited data are available on the incidence, predictors, and causes of 30-day readmission after hospitalization for CLI. Methods -Hospitalizations for a primary diagnosis of CLI during which patients underwent endovascular or surgical therapy (revascularization and/or amputation) and were discharged alive were identified in the 2013-2014 Nationwide Readmissions Databases...
May 2, 2017: Circulation
https://www.readbyqxmd.com/read/28465287/prevalence-of-subclinical-coronary-artery-disease-in-masters-endurance-athletes-with-a-low-atherosclerotic-risk-profile
#15
Ahmed Merghani, Viviana Maestrini, Stefania Rosmini, Andrew T Cox, Harshil Dhutia, Rachel Bastiaenen, Sarojini David, Tee Joo Yeo, Rajay Narain, Aneil Malhotra, Michael Papadakis, Mathew G Wilson, Maite Tome, Khaled AlFakih, James C Moon, Sanjay Sharma
Background -Studies in middle aged and older (masters) athletes with atherosclerotic risk factors for coronary artery disease (CAD) report higher coronary artery calcium (CAC) scores compared with sedentary individuals. Few studies have assessed the prevalence of CAD in masters athletes with a low atherosclerotic risk profile. Methods -We assessed 152 masters athletes aged 54.4±8.5 years (70% male) and 92 controls of similar age, sex and low Framingham 10 year CAD risk scores with an echocardiogram, exercise stress test, CT coronary angiogram, and cardiovascular magnetic resonance imaging (CMRI) with late gadolinium enhancement (LGE) and a 24-hour Holter...
May 2, 2017: Circulation
https://www.readbyqxmd.com/read/28465286/estimation-of-eligibility-for-pcsk9-inhibitors-and-associated-costs-based-on-the-fourier-trial-insights-from-the-department-of-veterans-affairs
#16
Salim S Virani, Julia M Akeroyd, Vijay Nambi, Paul A Heidenreich, Pamela B Morris, Khurram Nasir, Erin D Michos, Vera A Bittner, Laura A Petersen, Christie M Ballantyne
In the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial,1 treatment with evolocumab resulted in a 15% relative (1.5% absolute) risk reduction of major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) at a median follow-up of 2.2 years. This trial included patients with LDL-C≥70mg/dL or non-HDL-C ≥100mg/dL on at least moderate-intensity statins. It is not known what proportion of ASCVD patients would qualify for evolocumab based on FOURIER entry criteria and how eligibility would change if maximal doses of evidence-based lipid lowering therapies were required...
May 2, 2017: Circulation
https://www.readbyqxmd.com/read/28461624/loss-of-cardio-protective-effects-at-the-adamts7-locus-due-to-gene-smoking-interactions
#17
Danish Saleheen, Wei Zhao, Robin Young, Christopher P Nelson, Weang Kee Ho, Jane F Ferguson, Asif Rasheed, Kristy Ou, Sylvia T Nurnberg, Robert C Bauer, Anuj Goel, Ron Do, Alexandre F R Stewart, Jaana Hartiala, Weihua Zhang, Gudmar Thorleifsson, Rona J Strawbridge, Juha Sinisalo, Stavroula Kanoni, Sanaz Sedaghat, Eirini Marouli, Kati Kristiansson, Jing Hua Zhao, Robert Scott, Dominique Gauguier, Svati H Shah, Albert Vernon Smith, Natalie Van Zuydam, Amanda J Cox, Christina Willenborg, Thorsten Kessler, Lingyao Zeng, Michael A Province, Andrea Ganna, Lars Lind, Nancy L Pedersen, Charles C White, Anni Joensuu, Marcus Edi Kleber, Alistair S Hall, Winfried März, Veikko Salomaa, Christopher O'Donnell, Erik Ingelsson, Mary F Feitosa, Jeanette Erdmann, Donald W Bowden, Colin N A Palmer, Vilmundur Gudnason, Ulf de Faire, Pierre Zalloua, Nicholas Wareham, John R Thompson, Kari Kuulasmaa, George Dedoussis, Markus Perola, Abbas Dehghan, John C Chambers, Jaspal Kooner, Hooman Allayee, Panos Deloukas, Ruth McPherson, Kari Stefansson, Heribert Schunkert, Sekar Kathiresan, Martin Farrall, Philippe M Frossard, Daniel J Rader, Nilesh Samani, Muredach P Reilly
Background -Common diseases such as coronary heart disease (CHD) are complex in etiology. The interaction of genetic susceptibility with lifestyle factors may play a prominent role. However, gene-environment interactions for CHD have been difficult to identify. Here, we investigate interaction of smoking behavior, a potent lifestyle factor, with genotypes that have been shown to associate with CHD risk. Methods -We analyzed data on 60,919 CHD cases and 80,243 controls from 29 studies for gene-smoking interactions for genetic variants at 45 loci previously reported to associate with CHD risk...
May 1, 2017: Circulation
https://www.readbyqxmd.com/read/28455343/2017-acc-aha-hfsa-focused-update-of-the-2013-accf-aha-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice-guidelines-and-the-heart-failure-society-of-america
#18
REVIEW
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Monica M Colvin, Mark H Drazner, Gerasimos S Filippatos, Gregg C Fonarow, Michael M Givertz, Steven M Hollenberg, JoAnn Lindenfeld, Frederick A Masoudi, Patrick E McBride, Pamela N Peterson, Lynne Warner Stevenson, Cheryl Westlake
No abstract text is available yet for this article.
April 28, 2017: Circulation
https://www.readbyqxmd.com/read/28450351/prospective-study-of-adenosine-on-atrioventricular-nodal-conduction-in-pediatric-and-young-adult-patients-after-heart-transplant
#19
Jonathan N Flyer, Warren A Zuckerman, Marc E Richmond, Brett R Anderson, Tamar G Mendelsberg, Jennie M McAllister, Leonardo Liberman, Linda J Addonizio, Eric S Silver
Background -Supraventricular tachycardia (SVT) is common after heart transplant. Adenosine, the standard therapy for treating SVT in children and adults without transplant, is relatively contraindicated post-transplant due to a presumed risk of prolonged atrioventricular (AV) block in denervated hearts. This study tested whether adenosine caused prolonged asystole after transplant and if it was effective in blocking AV nodal conduction in these patients. Methods -This was a single center prospective clinical study including healthy heart transplant recipients ages 6 months - 25 years presenting for routine cardiac catheterization during 2015 - 2016...
April 27, 2017: Circulation
https://www.readbyqxmd.com/read/28450350/cholesterol-efflux-capacity-hdl-particle-number-and-incident-cardiovascular-events-an-analysis-from-the-jupiter-trial-justification-for-the-use-of-statins-in-prevention-an-intervention-trial-evaluating-rosuvastatin
#20
Amit V Khera, Olga Demler, Steve J Adelman, Heidi L Collins, Robert J Glynn, Paul M Ridker, Daniel J Rader, Samia Mora
Background -Recent failures of drugs that raised high-density lipoprotein (HDL) cholesterol levels to reduce cardiovascular events in clinical trials have led to increased interest in alternative indices of HDL quality, such as cholesterol efflux capacity, and HDL quantity, such as HDL particle number. However, no studies have directly compared these metrics in a contemporary population that includes potent statin therapy and low LDL cholesterol. Methods -HDL cholesterol levels, apolipoprotein A-I (apoA-I), cholesterol efflux capacity, and HDL particle number were assessed at baseline and 12 months in a nested case-control study of the JUPITER trial, a randomized primary prevention trial that compared rosuvastatin treatment to placebo in individuals with normal LDL cholesterol but increased C-reactive protein levels...
April 27, 2017: Circulation
journal
journal
20069
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"